Clinical trial
Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic…
NCT00245648 · NYU Langone Health, Other · Completed
Key facts
| NCT number | NCT00245648 |
|---|---|
| Title | Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI |
| Official title | Female Sex is an Independent Predictor of Death and Bleeding Among Fibrinolytic Treated Patients With AMI; Results of the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries - V Trial |
| Lead sponsor | NYU Langone Health, Other |
| Collaborators | The Cleveland Clinic Centocor, Inc. Industry Eli Lilly and Company |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Myocardial Infarction |
| Intervention type | Drug |
| Interventions | fibrinolytic therapy or combination reduced fibrinolytic therapy |
| Start date | Jun 1, 2001 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Oct 28, 2005 |
| Last update posted | Oct 4, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: